Abstract
Transcatheter aortic valve implantation (TAVI) volumes continue to grow around the world with TAVI now a first line therapy for treatment of aortic stenosis. With this growth, more clinical factors that may have impact on outcome related to the procedure are becoming better understood. Incidence, clinical impact and predictors of thrombocytopenia after transcatheter aortic valve replacementInternational Journal of CardiologyVol. 352PreviewThrombocytopenia is a common, yet poorly understood, complication after transcatheter aortic valve replacement (TAVR). Balloon-expandable transcatheter heart valve has been associated with higher incidence of thrombocytopenia, compared with self-expandable valves. The aim of this study was to analyze the incidence, clinical impact and predictors of acquired thrombocytopenia in patients undergoing TAVR. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
